Figure 8

Inhibiting c-Jun N-terminal kinase (JNK) activity using AS601245 significantly attenuated lipopolysaccharide (LPS)-sensitized hypoxic-ischemic (HI) brain injury. AS601245 treatment at a dose of 20 mg/kg (n = 12) was more effective than 40 mg/kg (n = 11) in attenuating cortical injury (Nissl stain, upper panel), increasing myelination (MBP, middle panel), and decreasing astrogliosis (GFAP, lower panel) than vehicle treatment (n =15) on P17 after LPS-sensitized HI on P5. Scale bar = 200 μm for MBP and 100 μm for GFAP. Values are means ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05. GFAP, glial fibrillary acidic protein; MBP, myelin basic protein.